Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Want to cut your energy bills? Here’s how five experts are doing it 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
CANTON, Mass., March 10, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET. The Company will discuss its financial results for 2015 and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (866) 864-3220 (U.S.) or (704) 908-0478 (International). An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
